Printer Friendly

Trichotillomania: targeting the root of the disorder.

An estimated 1% of Americans have trichotillomania (TTM), an impulsecontrol disorder in which patients experience pleasure or gratification from recurrently pulling out their own hair, resulting in noticeable hair loss. (1), (2) This disorder is more commonly diagnosed in women, likely reflecting treatmentseeking bias; women may be more likely to seek care for TTM because of social stigma associated with hair loss. (2) Avulsion of hair usually occurs at the scalp, but also can be seen in multiple sites, including eyebrows, eyelashes, beards, and pubic regions; the number of sites typically increases with the patient's age. (3)

The lifetime prevalence of comorbid axis I disorders in patients with TTM is 82%. (3) Because of this, TTM often is first encountered in a psychiatric setting. Psychiatrists should have knowledge of TTM diagnosis and treatment because they may be the only point of care for TTM patients. When considering a TTM diagnosis, be aware that in some cultures rending hair is a mourning ritual or a rite of passage. (3)

Evidence for cognitive therapies

Behavioral models suggest TTM behaviors are learned and maintained by both classical and operant conditioning. Therapies that target the cognitive processes that trigger urges to pull, the avulsion of hair, and recognizing the consequences have the best empirical support. (3)

Habit reversal training (HRT) is considered the most effective treatment for TTM. (3) One trial found a single 2-hour HRT intervention resulted in greater reductions in hair pulling episodes and higher remission rates compared with placebo.3 HRT trains patients to create a competing response, such as fist clenching, that is incompatible and blocks the undesired response.

Other therapeutic approaches to TTM include acceptance and commitment therapy, cognitive-behavioral therapy (CBT), and dialectical behavioral therapy-enhanced HRT. Evidence is most robust for CBT-HRT; randomized controlled trials found a statistically significant reduction in TTM in patients receiving CBT-HRT. (3) One review suggests CBT-HRT should be considered first-line therapy for TTM. (3)

Pharmacologic options

Although no medications are FDA-approved for treating TTM, options include clomipramine, olanzapine, fluoxetine, pimozide, inositol, naltrexone, and N-acetylcysteine. (2), (3) The most robust trials of pharmacotherapy monotherapy were for N-acetylcysteine and naltrexone; both medications had significantly greater reduction in hair-pulling symptoms compared with placebo.3 Some evidence suggests combined pharmacotherapy and psychotherapy might be an effective approach.2.3

References

(1.) Diagnostic and statistical manual of mental disorders, 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.

(2.) Woods DW, Flessner C, Franklin ME, et al. Understanding and treating trichotillomania: what we know and what we don't know Psychiatr OM North Am. 2006;29(2):487-501, ix.

(3.) Duke DC, Keeley ML, Geffken GR, et al. Trichotillomarda: a current review. Clin Psychol Rev. 2010;30(4181-193.

Stephanie Peglow, DO, and Christian DeFilippo, MD

Dr. Peglow is a Second-Year Psychiatry Resident and Dr. DeFilippo is Assistant Professor of Psychiatry and Behavioral Sciences, Eastern Virginia Medical School, Norfolk, VA.

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
COPYRIGHT 2012 Quadrant Healthcom, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Pearls
Author:Peglow, Stephanie; DeFilippo, Christian
Publication:Current Psychiatry
Article Type:Disease/Disorder overview
Date:Jul 1, 2012
Words:503
Previous Article:Strategies for managing patients with chronic subjective dizziness.
Next Article:This month's instant poll.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters